Q-omics provides the consensus-scored ZNF605 profile across patient tissues and cancer cell-line models. ZNF605 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF605 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF605 RNA expression shows 21,208 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, and THYM as cancer lineages where ZNF605 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF605 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF605 survival associations across molecular data types. ZNF605 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF605 RNA expression–survival associations across cancer types. High ZNF605 expression shows unfavorable associations in LIHC, KIRC, LUAD, COAD and MESO, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF605 RNA expression.
This table summarizes ZNF605 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF605. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF605 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, LUSC, KIRP and LUAD. The LIHC box plot shows higher ZNF605 RNA expression in tumor versus normal tissue (log2 FC = +1.052, t-test p < 0.001).
This table shows molecular features associated with ZNF605 in patient tissues and cancer cell lines. In patient samples, ZNF605 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF605 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUSC.
